Compare XELB & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XELB | FEMY |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 12.0M |
| IPO Year | 2011 | 2021 |
| Metric | XELB | FEMY |
|---|---|---|
| Price | $1.42 | $3.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $5.50 |
| AVG Volume (30 Days) | ★ 75.6K | 35.0K |
| Earning Date | 04-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.37 | 44.71 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | $102.11 | $105.16 |
| Revenue Next Year | N/A | $200.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $0.74 | $0.29 |
| 52 Week High | $2.66 | $6.29 |
| Indicator | XELB | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 33.58 | 43.88 |
| Support Level | $1.25 | $0.48 |
| Resistance Level | $1.62 | $4.78 |
| Average True Range (ATR) | 0.15 | 0.37 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 2.30 | 0.46 |
Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.